Work

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Year: 2005

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v106.11.3338.3338

Authors: Steven Grant, Daniel Sullivan, David Roodman, Robert Stuart, Edward B. Perkins, Viswanathan Ramakrishnan, John Wright, A. Dimitrios Colevas, John D. Roberts

Institutions: Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, University of South Florida, Moffitt Cancer Center, UPMC Hillman Cancer Center, Medical University of South Carolina, MUSC Hollings Cancer Center, National Cancer Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4231131937

FWCI: 0.203

Cites:

Cited by: 2

Related to: 10